$MBRX
Moleculin Biotech, Inc.

2022 Q4 Form 10-Q Financial Statement

#000143774922026888 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.838M $3.087M $1.992M
YoY Change 42.47% 52.75% 20.0%
% of Gross Profit
Research & Development $4.178M $5.965M $3.179M
YoY Change 31.42% 45.67% 77.6%
% of Gross Profit
Depreciation & Amortization $32.00K $32.00K $34.00K
YoY Change -5.88% -21.95% -32.0%
% of Gross Profit
Operating Expenses $7.048M $9.084M $5.205M
YoY Change 35.41% 47.54% 48.71%
Operating Profit -$9.084M
YoY Change 47.54%
Interest Expense $277.0K $454.0K $2.370M
YoY Change -88.31% -74.28% 175.58%
% of Operating Profit
Other Income/Expense, Net $1.000K $19.00K $10.00K
YoY Change -90.0% 46.15%
Pretax Income -$6.770M -$8.611M -$2.825M
YoY Change 139.65% 96.64% 7.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.770M -$8.611M -$2.825M
YoY Change 139.65% 96.64% 7.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.30
Diluted Earnings Per Share -$0.24 -$300.8K -$98.79K
COMMON SHARES
Basic Shares Outstanding 28.63M 28.61M 28.58M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.15M $50.39M $70.90M
YoY Change -39.15% -32.97% 367.39%
Cash & Equivalents $43.10M $50.40M $70.90M
Short-Term Investments
Other Short-Term Assets $1.403M $1.751M $1.594M
YoY Change -11.98% -7.45% -14.3%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $45.60M $53.49M $72.50M
YoY Change -37.11% -30.59% 321.54%
LONG-TERM ASSETS
Property, Plant & Equipment $275.0K $306.0K $338.0K
YoY Change -18.64% -13.31% -30.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $11.83M $11.88M $11.59M
YoY Change 2.01% 2.12% -2.03%
TOTAL ASSETS
Total Short-Term Assets $45.60M $53.49M $72.50M
Total Long-Term Assets $11.83M $11.88M $11.59M
Total Assets $57.42M $65.37M $84.09M
YoY Change -31.71% -26.3% 189.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.095M $3.568M $1.364M
YoY Change 53.59% 156.69% 20.81%
Accrued Expenses $2.724M $2.794M $2.258M
YoY Change 20.64% 23.3% 26.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.819M $6.362M $3.622M
YoY Change 33.05% 74.02% 24.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $412.0K $593.0K $1.475M
YoY Change -72.07% -84.34% -82.34%
Total Long-Term Liabilities $412.0K $593.0K $1.475M
YoY Change -72.07% -84.34% -82.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.819M $6.362M $3.622M
Total Long-Term Liabilities $412.0K $593.0K $1.475M
Total Liabilities $5.231M $6.955M $5.097M
YoY Change 2.63% -6.56% -54.78%
SHAREHOLDERS EQUITY
Retained Earnings -$101.8M -$95.10M -$72.81M
YoY Change 39.82% 35.86% 27.93%
Common Stock $154.0M $153.5M $151.8M
YoY Change 1.48% 1.5% 103.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.19M $58.42M $78.99M
YoY Change
Total Liabilities & Shareholders Equity $57.42M $65.37M $84.09M
YoY Change -31.71% -26.3% 189.66%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$6.770M -$8.611M -$2.825M
YoY Change 139.65% 96.64% 7.01%
Depreciation, Depletion And Amortization $32.00K $32.00K $34.00K
YoY Change -5.88% -21.95% -32.0%
Cash From Operating Activities -$7.256M -$7.577M -$4.258M
YoY Change 70.41% 76.7% 36.47%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$19.00K
YoY Change -100.0% -5.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 -$19.00K
YoY Change -100.0% 90.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -11.00K 0.000
YoY Change -54.17% -100.0%
NET CHANGE
Cash From Operating Activities -7.256M -7.577M -4.258M
Cash From Investing Activities 0.000 0.000 -19.00K
Cash From Financing Activities 0.000 -11.00K 0.000
Net Change In Cash -7.256M -7.588M -4.277M
YoY Change 69.65% 75.97% -282.0%
FREE CASH FLOW
Cash From Operating Activities -$7.256M -$7.577M -$4.258M
Capital Expenditures $0.00 $0.00 -$19.00K
Free Cash Flow -$7.256M -$7.577M -$4.239M
YoY Change 71.17% 76.7% 36.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28627827
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28627827
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28578338
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28578338
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6159000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
403000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2021Q3 mbrx License Agreements Expense
LicenseAgreementsExpense
56000 usd
dei Document Type
DocumentType
10-Q
dei Trading Symbol
TradingSymbol
MBRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28627827
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50392000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70903000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3101000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1594000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
53493000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
72497000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
306000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
338000 usd
CY2022Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 usd
CY2021Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
11148000 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37758
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4671997
dei Entity Address Address Line1
EntityAddressAddressLine1
5300 Memorial Drive, Suite 950
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77007
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
300-5160
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
425000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
107000 usd
CY2022Q3 us-gaap Assets
Assets
65372000 usd
CY2021Q4 us-gaap Assets
Assets
84090000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3568000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1364000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2794000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2258000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6362000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3622000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
365000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
63000 usd
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
228000 usd
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1412000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
6955000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
5097000 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
3000 usd
CY2021Q4 us-gaap Aoci Before Tax Attributable To Parent
AociBeforeTaxAttributableToParent
41000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95065000 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
29000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
29000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
153450000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
151733000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72810000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
58417000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
78993000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65372000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84090000 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
CY2021Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5965000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4095000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14790000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11239000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3087000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2021000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8704000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6394000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32000 usd
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
130000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9084000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6157000 usd
us-gaap Operating Expenses
OperatingExpenses
23592000 usd
us-gaap Operating Expenses
OperatingExpenses
17763000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9084000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6157000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-23592000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17763000 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-421000 usd
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1678000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1184000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4428000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
33000 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
87000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
114000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
236000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8611000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4379000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22255000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13069000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28627610
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28573476
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28596501
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26302638
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8611000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4379000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22255000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13069000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-16000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
23000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
24000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-38000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-26000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8630000 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4395000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22293000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13095000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22255000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13069000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
98000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
130000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1740000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1817000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1184000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4428000 usd
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
96000 usd
mbrx Operating Lease Noncash Expense Net
OperatingLeaseNoncashExpenseNet
102000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1507000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-133000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2204000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
261000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
425000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
361000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20383000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14693000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
63000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
74685000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-23000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74724000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-38000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-26000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20511000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
60005000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70903000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15173000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50392000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75178000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
78993000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
527000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-6867000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
12000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
72665000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-12000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
514000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-6777000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-31000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
66359000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-11000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
699000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8611000 usd
CY2021Q4 mbrx Prepaid Sponsored Research Current
PrepaidSponsoredResearchCurrent
474000 usd
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
938000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
58417000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17760000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
589000 usd
CY2022Q3 mbrx Vendor Prepayments And Deposits
VendorPrepaymentsAndDeposits
807000 usd
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
23000 usd
CY2021Q4 mbrx Vendor Prepayments And Deposits
VendorPrepaymentsAndDeposits
486000 usd
CY2022Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
6000 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74684000 usd
CY2021Q1 mbrx Stockholders Equity Adjustments Reverse Stock Split
StockholdersEquityAdjustmentsReverseStockSplit
0 usd
CY2021Q1 mbrx Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
116000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
405000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4445000 usd
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-4000 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
88516000 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000 usd
CY2021Q2 mbrx Subscription Of Common Stock Value
SubscriptionOfCommonStockValue
0 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
433000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-4244000 usd
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
84700000 usd
CY2021Q3 mbrx Stock Issued During Period Value Issued For Consulting Agreement
StockIssuedDuringPeriodValueIssuedForConsultingAgreement
0 usd
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-23000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
977000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-4379000 usd
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-16000 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
81259000 usd
CY2022Q3 mbrx Number Of Core Drug Technologies
NumberOfCoreDrugTechnologies
3 pure
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14700000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95100000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20400000 usd
CY2022Q3 mbrx Prepaid Sponsored Research Current
PrepaidSponsoredResearchCurrent
1346000 usd
CY2022Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
4000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;"><b>Use of Estimates -</b> The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors <em style="font: inherit;"> may </em>affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often <em style="font: inherit;"> may </em>yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process <em style="font: inherit;"> may </em>result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:18pt;"> </p>
us-gaap Net Income Loss
NetIncomeLoss
-22300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-13100000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50400000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1594000 usd
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
22000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3101000 usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6000000.0
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4100000
CY2022Q3 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1336000 usd
CY2021Q4 mbrx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1005000 usd
CY2022Q3 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
803000 usd
CY2021Q4 mbrx Accrued Legal Regulatory Professional And Other Current
AccruedLegalRegulatoryProfessionalAndOtherCurrent
442000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
433000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
606000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
96000 usd
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
110000 usd
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
109000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2794000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2258000 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
72000 usd
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
48000 usd
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
49489
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
699000 usd
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
977000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1740000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1817000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
842832
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.26
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.49
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
33000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
29000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
91000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
87000 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
7000 usd
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
7000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
22000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
22000 usd
CY2022Q3 us-gaap Lease Cost
LeaseCost
40000 usd
CY2021Q3 us-gaap Lease Cost
LeaseCost
36000 usd
us-gaap Lease Cost
LeaseCost
113000 usd
us-gaap Lease Cost
LeaseCost
109000 usd
CY2022Q2 mbrx Lessee Operating Lease Monthly Rent Average Increase Rate
LesseeOperatingLeaseMonthlyRentAverageIncreaseRate
0.03 pure
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
12000 usd
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
10000 usd
us-gaap Sublease Income
SubleaseIncome
32000 usd
us-gaap Sublease Income
SubleaseIncome
31000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
21000 usd
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
35000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
91000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
103000 usd
CY2022Q3 mbrx License Agreements Expense
LicenseAgreementsExpense
56000 usd
mbrx License Agreements Expense
LicenseAgreementsExpense
189000 usd
mbrx License Agreements Expense
LicenseAgreementsExpense
150000 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
mbrx-20220930_cal.xml Edgar Link unprocessable
0001437749-22-026888-index-headers.html Edgar Link pending
0001437749-22-026888-index.html Edgar Link pending
0001437749-22-026888.txt Edgar Link pending
0001437749-22-026888-xbrl.zip Edgar Link pending
ex_416187.htm Edgar Link pending
ex_416188.htm Edgar Link pending
ex_416189.htm Edgar Link pending
ex_416190.htm Edgar Link pending
ex_444526.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mbrx-20220930.xsd Edgar Link pending
mbrx20220930_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
moleculinnewlogoresized.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
mbrx-20220930_def.xml Edgar Link unprocessable
mbrx-20220930_lab.xml Edgar Link unprocessable
mbrx-20220930_pre.xml Edgar Link unprocessable
mbrx20220930_10q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending